C-Reactive Protein Downregulates TRAIL, a Cytokine with Key Role in Cancer Immune Surveillance 

Get Permission

C-reactive protein is a biomarker of acute and chronic inflammation that is frequently elevated in patients with cancer. In a study reported in Clinical Cancer Research, Secchiero and colleagues found that increased levels of C-reactive protein were associated with downregulation of TRAIL, a cytokine that plays a key role in immune surveillance against tumors.

The investigators showed that exposure in vitro to increasing C-reactive protein concentrations resulted in downregulation of TRAIL expression, at both the mRNA and protein level, in primary peripheral blood mononuclear cells and CD14-positive monocytes. TRAIL downregulation was not due to a specific toxicity or to contaminating lipopolysaccharide. C-reactive protein also downregulated TRAIL expression and release in CD14-positive monocytes after exposure to interferon-α, a potent inducer of TRAIL.

TRAIL downregulation by C-reactive protein was accompanied by a significant increase in early response growth protein-1 (Egr-1) level. Egr-1 overexpression consistently reduced TRAIL mRNA and knockdown of Egr-1 offset the ability of C-reactive protein to downregulate TRAIL, indicating that the effect of CRP on TRAIL occurs via an Egr-1-dependent pathway.

The investigators concluded, “Our findings suggest that a chronic elevation of [C-reactive protein], which occurs during systemic inflammation and often in patients with cancer, might contribute to promote cancer development and/or progression by downregulating TRAIL in immune cells.” ■

Secchiero P, et al: Clin Cancer Res 19:1949-1959, 2013





By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.